delta one t cells

Delta One T cells (DOT cells) are a population of γδ T lymphocytes specifically enriched for the Vδ1+ subset, developed for use in adoptive cellular immunotherapy. They are expanded ex vivo from donor-derived peripheral blood samples using a cytokine and antibody protocol that can achieve a high yield of cytotoxic Vδ1+ cells. These clinical-grade cells express natural cytotoxicity receptors such as NKp30 and NKp44, and exert antitumor activity primarily through NK receptor engagement (notably DNAM-1) rather than their T-cell receptor. Studies show DOT cells can infiltrate tumors, produce IFNγ and TNFα without IL-17, and suppress tumor growth in preclinical chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) models. Their main therapeutic rationale is the targeting of hematological malignancies and solid tumors via innate-like cytotoxicity[1][3][7].

Other names

dot cellsVδ1+ t cellsdelta one t cells